STAT+: After warning letter, Whoop and FDA in discussions about controversial blood pressure feature

Wearable maker Whoop is in ongoing discussions with the FDA regarding a blood pressure monitoring feature launched last year. The FDA issued a warning letter claiming the feature is a medical device requiring agency review, while Whoop contends it is exempt as a wellness product. The dispute remains unresolved despite the FDA's January guidance update on general wellness products.